Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies
S Frantz, MJ Hundertmark… - European heart …, 2022 - academic.oup.com
Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Empagliflozin in acute myocardial infarction: the EMMY trial
D von Lewinski, E Kolesnik, NJ Tripolt… - European heart …, 2022 - academic.oup.com
Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …
failure and for death in patients with symptomatic heart failure. However, trials investigating …
Diagnosis and treatment of acute coronary syndromes: a review
DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …
Dapagliflozin in myocardial infarction without diabetes or heart failure
Background In patients with acute myocardial infarction (MI), therapies that could further
reduce the risk of adverse cardiovascular and metabolic outcomes are needed. Methods In …
reduce the risk of adverse cardiovascular and metabolic outcomes are needed. Methods In …
[HTML][HTML] Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Background Patients with acute myocardial infarction (MI) are at risk for developing heart
failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose …
failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose …
[HTML][HTML] Ischemic cardiomyopathy and heart failure after acute myocardial infarction
Abstract Purpose of Review Ischemic cardiomyopathy refers to systolic left ventricular
dysfunction in the setting of obstructive coronary artery disease and represents the most …
dysfunction in the setting of obstructive coronary artery disease and represents the most …
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week
Abstract Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …
Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association
AA Damluji, DE Forman, TY Wang, J Chikwe… - Circulation, 2023 - Am Heart Assoc
Diagnostic and therapeutic advances during the past decades have substantially improved
health outcomes for patients with acute coronary syndrome. Both age-related physiological …
health outcomes for patients with acute coronary syndrome. Both age-related physiological …
[HTML][HTML] Left ventricular remodeling after myocardial infarction: from physiopathology to treatment
Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …
incidence relatively high in developed countries and rapidly growing in developing …